<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896921</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00056162</org_study_id>
    <nct_id>NCT01896921</nct_id>
  </id_info>
  <brief_title>Switch to Maraviroc + Integrase Inhibitor</brief_title>
  <official_title>Switch to Maraviroc and Integrase Strand Transfer Inhibitor Combination Therapy (a Triple Class-Sparing Regimen) for the Treatment of HIV-1-Infected Patients on Suppressive Antiretroviral Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study proposes to evaluate the combination of maraviroc with an integrase
      strand transfer inhibitor (either raltegravir or dolutegravir) in antiretroviral-experienced
      patients to document the efficacy, safety, and tolerability of this combination in order to
      provide clinicians with a treatment regimen that minimizes the risk of metabolic
      complications by avoidance of NRTI/NNRTIs and PIs. The development of an alternative ART
      regimen which lessens the risk of metabolic complications could improve long-term adherence
      and reduce the risk of certain co-morbidities associated with long-term ART use. If this new
      combination is found to be as efficacious as the standard regimen with enhanced tolerability
      and improved metabolic effects, there is great potential for altering the current practice of
      HIV medicine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Description of the study design:

      The study will enroll 30 HIV-infected patients on a stable ART regimen with a suppressed HIV
      RNA &lt; 50 copies/ml for at least one year. Patients will be switched to the experimental
      regimen (maraviroc 300 mg twice a day plus either raltegravir 400 mg twice a day or
      dolutegravir 50 mg once a-day) and followed for 96 weeks. The decision to use raltegravir or
      dolutegravir will be left to investigator/subject preference, as the two integrate inhibitors
      are largely interchangeable aside from twice daily (raltegravir) vs. daily (dolutegravir)
      dosing.

      Primary endpoint:

        -  The primary endpoint is the proportion of patients virologically suppressed (HIV RNA &lt;
           50 copies/ml) at 48 weeks.

      Definitions:

        -  Virologic suppression is an HIV RNA &lt; 50 copies/ml.

        -  Virologic failure is an HIV RNA ≥ 50 copies/ml confirmed on 2 separate occasions,
           separated by &gt; 1 week after viral suppression.

      Secondary endpoints:

        -  The percent change in total cholesterol, LDL, and HDL at 48 and 96 weeks.

        -  The number of adverse events.

        -  The proportion of patients who are virologically suppressed (HIV RNA &lt; 50 copies/ml) at
           96 weeks.

      Exploratory endpoints:

        -  Telomerase activity and telomere length measured at baseline and 24, 48, and 96 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2013</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Virologically Suppressed (HIV RNA &lt;50 Copies/ml) at 48 Weeks.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of patients virologically suppressed (HIV RNA &lt;50 copies/ml) at 48 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change in Total Cholesterol, LDL, and HDL</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Are Virologically Suppressed (HIV RNA &lt; 50 Copies/ml)</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Telomerase Activity and Telomere Length.</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Maraviroc + Raltegravir or Dolutegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Switch to Maraviroc + Raltegravir or Dolutegravir</intervention_name>
    <description>Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
    <arm_group_label>Maraviroc + Raltegravir or Dolutegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  Age between 18 and 75 years

          -  CD4 count nadir ≥ 250 cells/mm3

          -  HIV RNA ≤ 50 copies/ml for ≥ 12 months while taking any ART regimen

             o One virologic blip ≤ 400 copies/ml permissible within the 12 months

          -  CCR5 tropic virus as defined by:

               -  trofile/tropism testing if available, OR

               -  DNA trofile if no trofile/tropism test available and CD4 nadir 250-499 cells/mm3,
                  OR

               -  CD4 nadir ≥ 500 cells/mm3

        Exclusion Criteria:

          -  Age &lt; 18 or &gt; 75 years

          -  CD4 count nadir &lt; 250 cells/mm3

          -  Dual/mixed or X4 tropic virus if tested prior to viral suppression or if performed by
             DNA trofile testing at any time

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2.5 times the
             upper limits of normal

          -  Women who:

               -  are currently pregnant or breastfeeding

               -  are of child-bearing age and do not agree to remain abstinent or use (or have
                  their partner use) an acceptable method of birth control throughout the study.
                  Acceptable method of birth control is defined as intrauterine device (IUD),
                  diaphragm with spermicide, contraceptive sponge, condom, vasectomy.

          -  History of any malignancy except non-melanoma skin cancer

          -  Concomitant use of drugs known to impact or be impacted in terms of pharmacokinetics
             or drug-drug interactions with either raltegravir or maraviroc. This includes:

               -  Inducers of UGT1A1 (such as rifampin, phenytoin, phenobarbital rifabutin, St.
                  John's wort)

               -  CYP3A inhibitors (such as ketoconazole, itraconazole, clarithromycin, nefazodone,
                  and telithromycin)

               -  CYP3A inducers (such as rifampin, carbamazepine, phenobarbital and phenytoin)

          -  Subject requires or is anticipated to require any of the prohibited medications noted
             in the protocol

          -  Enrollment in an experimental protocol having received investigational agents
             (antiretroviral or non-antiretroviral) within 30 days of study enrollment

          -  Chronic active hepatitis B infection as defined by presence of HBsAg

          -  Subject has a history or current evidence of any condition, therapy, laboratory
             abnormality or other circumstance that might interfere with the patient's
             participation for the full duration of the study, such that it is not in the best
             interest of the patient to participate.

          -  Subject is unlikely to adhere to the study procedures, keep appointments, or is
             planning to relocate during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Riedel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Institute of Human Virology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 27, 2013</study_first_submitted>
  <study_first_submitted_qc>July 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <results_first_submitted>July 16, 2019</results_first_submitted>
  <results_first_submitted_qc>November 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2019</results_first_posted>
  <last_update_submitted>November 1, 2019</last_update_submitted>
  <last_update_submitted_qc>November 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>David Riedel</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 26, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT01896921/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Maraviroc + Raltegravir or Dolutegravir</title>
          <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maraviroc + Raltegravir or Dolutegravir</title>
          <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="54" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Virologically Suppressed (HIV RNA &lt;50 Copies/ml) at 48 Weeks.</title>
        <description>Proportion of patients virologically suppressed (HIV RNA &lt;50 copies/ml) at 48 weeks.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Raltegravir or Dolutegravir</title>
            <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Virologically Suppressed (HIV RNA &lt;50 Copies/ml) at 48 Weeks.</title>
          <description>Proportion of patients virologically suppressed (HIV RNA &lt;50 copies/ml) at 48 weeks.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change in Total Cholesterol, LDL, and HDL</title>
        <time_frame>48 and 96 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>48 and 96 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Are Virologically Suppressed (HIV RNA &lt; 50 Copies/ml)</title>
        <time_frame>96 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Telomerase Activity and Telomere Length.</title>
        <time_frame>48 and 96 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>96 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc + Raltegravir or Dolutegravir</title>
          <description>Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks
Switch to Maraviroc + Raltegravir or Dolutegravir: Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Mechanical fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gregg Brogden</name_or_title>
      <organization>University of Maryland</organization>
      <phone>4107061660</phone>
      <email>gbrogden@ihv.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

